Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects

Manuscript Number: 

19-0228R1

Author(s): 
Jae Eun Ahn, Robert Alexander, Michael A. Brodney, Danny Chen, Ping He, Claire Leurent, Jessica Mancuso, Richard A. Margolin, Ruolun Qiu, Ekaterina Tankisheva

Disclosures

Jae Eun Ahn

  • Equity:
    Pfizer Stocks
    Sponsors:
    Pfizer, Inc.

Robert Alexander

  • Equity:
    Own stock in Pfizer
    Sponsors:
    Was an employee of Pfizer while the study was conducted

Michael A. Brodney

  • Equity:
    I own stock at Pfizer

Danny Chen

  • Equity:
    own Pfizer stocks
    Sponsors:
    Employed by Pfizer

Ping He

  • Equity:
    I was Pfizer employee and own PFE stocks
    Sponsors:
    I was Pfizer employee at the time of the work related to this manuscript

Claire Leurent

  • Equity:
    As an ex-Pfizer employee I detain stocks in Pfizer

Jessica Mancuso

  • Equity:
    JM is an employee of Pfizer Inc and thus owns stock or stock options in Pfizer Inc.

Richard A. Margolin

  • Equity:
    I own Pfizer, Merck, Johnson and Johnson stock.
    Sponsors:
    Former employee (until April 2018)

Ruolun Qiu

  • Equity:
    Pfizer Stocks
    Sponsors:
    Pfizer, Inc

Ekaterina Tankisheva

  • Equity:
    equities and stock options in Pfizer Inc.
    Sponsors:
    employed by Pfizer Inc. - Clinical Research Physician, Belgium, Pfizer Clinical Research Unit.